Gold coated poly (ε-caprolactonediol) based polyurethane nanofibers for controlled release of temozolomide

Co-loading of Temozolomide with Oleuropein or rutin into polylactic acid core-shell nanofiber webs inhibit glioblastoma cell by controlled release

Glioblastoma (GB) has susceptibility to post-surgical recurrence. Therefore, local treatment methods are required against recurrent GB cells in the post-surgical area. In this study, we developed a nanofiber-based local therapy against GB cells using Oleuropein (OL), and rutin and their combinations with Temozolomide (TMZ). The polylactic acid (PLA) core-shell nanofiber webs were encapsulated with OL (PLAOL), rutin (PLArutin), and TMZ (PLATMZ) by an electrospinning process. A SEM visualized the morphology and the total immersion method determined the release characteristics of PLA webs. Real-time cell tracking analysis for cell growth, dual Acridine Orange/Propidium Iodide staining for cell viability, a scratch wound healing assay for migration capacity, and a sphere formation assay for tumor spheroid aggressiveness were used. All polymeric nanofiber webs had core-shell structures with an average diameter between 133 ± 30.7-139 ± 20.5 nm. All PLA webs promoted apoptotic cell death, suppressed cell migration, and spheres growth (p < 0.0001). PLAOL and PLATMZ suppressed GB cell viability with a controlled release that increased over 120 h, while PLArutin caused rapid cell inhibition (p < 0.0001). Collectively, our findings suggest that core-shell nano-webs could be a novel and effective therapeutic tool for the controlled release of OL and TMZ against recurrent GB cells.

Electrospun nanofibers for 3-D cancer models, diagnostics, and therapy

As one of the leading causes of global mortality, cancer has prompted extensive research and development to advance efficacious drug discovery, sustained drug delivery and improved sensitivity in diagnosis. Towards these applications, nanofibers synthesized by electrospinning have exhibited great clinical potential as a biomimetic tumor microenvironment model for drug screening, a controllable platform for localized, prolonged drug release for cancer therapy, and a highly sensitive cancer diagnostic tool for capture and isolation of circulating tumor cells in the bloodstream and for detection of cancer-associated biomarkers. This review provides an overview of applied nanofiber design with focus on versatile electrospinning fabrication techniques. The influence of topographical, physical, and biochemical properties on the function of nanofiber assemblies is discussed, as well as current and foreseeable barriers to the clinical translation of applied nanofibers in the field of oncology.

Temozolomide: an Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods

Temozolomide (TMZ) is an imidazotetrazine prodrug used to treat glioblastoma multiforme. Its physicochemical prop-erties and small size confer the ability to cross the blood-brain barrier. The antitumor activity depends on pH-dependent hydrolysis of the methyldiazonium cation, which is capable of methylating purine bases (O6-guanine; N7-guanine, and N3-adenine) and causing DNA damage and cell death. TMZ is more stable in acidic media (pH ≤ 5.0) than in basic media (pH ≥ 7.0) due to the protonated form that minimizes the catalytic process. Because of this, TMZ has high oral bioavailability, but it has a half-life of 1.8 h and low brain distribution (17.8%), requiring a repeated dos-ing regimen that limits its efficacy and increases adverse events. Drug delivery Nanosystems (DDNs) improve the phys-icochemical properties of TMZ and may provide controlled and targeted delivery. Therefore, DDNs can increase the efficacy and safety of TMZ. In this context, to ensure the efficiency of DDNs, analytical methods are used to evaluate TMZ pharmacokinetic parameters, encapsulation efficiency, and the release profile of DDNs. Among the methods, high-performance liquid chromatography is the most used due to its detection sensitivity in complex matrices such as tissues and plasma. Micellar electrokinetic chromatography features fast analysis and no sample pretreatment. Spec-trophotometric methods are still used to determine encapsulation efficiency due to their low cost, despite their low sen-sitivity. This review summarizes the physicochemical and pharmacological properties of free TMZ and TMZ-loaded DDNs. In addition, this review addresses the main analytical methods employed to characterize TMZ in different ma-trices.

Adsorption, and controlled release of doxorubicin from cellulose acetate/polyurethane/multi-walled carbon nanotubes composite nanofibers

The cellulose acetate (CA)/poly (ε-caprolactone diol)/poly (tetramethylene ether) glycol-polyurethane (PCL-Diol/PTMG-PU)/multi-walled carbon nanotubes (MWCNTs) composite nanofibers were prepared via two-nozzle electrospinning on both counter sides of the collector. The performance of synthesized composite nanofibers was investigated as an environmental application and anticancer delivery system for the adsorption/release of doxorubicin (DOX). The synergic effect of MWCNTs and DOX incorporated into the nanofibers was investigated against LNCaP prostate cancer cells. The status of MWCNTs and DOX in composite nanofibers was demonstrated by SEM, FTIR and UV-vis determinations. The adsorption tests using nanofibrous adsorbent toward DOX sorption was evaluated under various DOX initial concentrations (100-2000 mg l^-1), adsorption times (5-120 min), and pH values (pH:2-9). Due to the fitting of isotherm and kinetic data with Redlich-Peterson and pseudo-second order models, both chemisorption and surface adsorption of DOX molecules mechanisms have been predicted. The drug release from both nanofibers and MWCNTs-loaded nanofibers was compared. The better drug sustained release profiles verified in the presence of composite nanofibers. LNCaP prostate cancer and L929 normal cells were treated to investigate the cytotoxicity and compatibility of synthesized composite nanofibers. The apoptosis/necrosis of hybrid nanofibers and MWCNTs loaded-nanofibers was investigated. The obtained results demonstrated the synergic effects of MWCNTs and DOX loaded-nanofibers on the LNCaP prostate cancer cells death.

Anticancer Effect in Human Glioblastoma and Antioxidant Activity of Petroselinum crispum L. Methanol Extract

Parsley (Petroselinum crispum L.) has been used as food, spices and in folkloric medicine. Several scientific researches have been focalized on anti-inflammatory, anti-proliferative, antioxidant and other pharmacological activities of parsley. The aim of the present study was to evaluate the phytochemical composition, antioxidant and anticancer activity of P. crispum L aqueous and methanol extracts against Human glioblastoma cells U87MG. Adhesion assay was realized on different protein matrices (fibrinogen, fibronectin and poly-L-lysine) and the anti-proliferative effect was performed. Compared to aqueous extract, the methanol extract presented an important level of phenol contents. Five phenolic compounds were found using HPLC-DAD with quinic acid as the most abounded followed by gallic acid, acacetin, protocatechuic acid and Cirsilineol with 120753.07 ± 27450; 190 ± 25; 53.83 ± 10; 13.7 ± 2.5 and 2 ± 0.3 µg/mL respectively.The DPPH, ABTS+, OH radical, Iron (II) chelation and FRAP assays exhibited that methanol extract show a modulate antioxidant activity. The methanol extract shows the highest ability to inhibit cell adhesion to different protein matrices. In addition, it was found as a potential anti-proliferative. These results suggest for the first time that P. crispum methanol extract presents anti-adhesion and anti-proliferative proprieties.

Fabrication of poly(acrylic acid) grafted-chitosan/polyurethane/magnetic MIL-53 metal organic framework composite core-shell nanofibers for co-delivery of temozolomide and paclitaxel against glioblastoma cancer cells

In the present study, the magnetic MIL-53 nanometal organic framework particles (NMOFs) were incorporated into poly(acrylic acid) grafted-chitosan/polyurethane (PA-g-CS/PU) core-shell nanofibers for controlled release of temozolomide (TMZ) and paclitaxel (PTX) against U-87 MG glioblastoma cells during chemotherapy/hyperthermia combined method. The synthesized magnetic MIL-53 NMOFs and NMOF-loaded nanofibers were characterized using X-ray diffraction (XRD), Brunauer-Emmett-Teller (BET), Fourier transformed infrared (FTIR), vibrating-sample magnetometer (VSM) and scanning electron microscopy (SEM) analysis. The TMZ and PTX release profiles from magnetic MIL-53 5 wt% loaded-CS-g-PAA-PTX-TMZ/PU fibers were investigated under acidic and physiological pH at temperatures of 37 and 43 °C. The effect of hyperthermia on the release rate of TMZ and PTX from magnetic nanofibers was investigated. An alternating magnetic field could induce the mild hyperthermia (43 °C) for the cells treated with magnetic MIL-53 5 wt% loaded-CS-g-PAA-PTX-TMZ/PU fibers during 10 min. The release data were best described by the non-Fickian diffusion of Korsmeyer-Peppas equation. The cell viability, flowcytometry and Bcl-2, Bax expression levels were investigated to obtain the optimum nanofibrous carrier for apoptosis of U-87 MG cells in vitro. The obtained results indicated that the synthesized magnetic MIL-53 NMOFs loaded- PA-g-CS/PU/TMZ-PTX nanofibers (shell flow rate: 0.8 mLh^-1) could be used as a targeted delivery of anticancer agents with maximum apoptosis of 49.6% of U-87 MG glioblastoma cells under AMF during chemotherapy/hyperthermia combination therapy.

Far-reaching advances in the role of carbon nanotubes in cancer therapy

Cancer includes a group of diseases involving unregulated cell growth with the potential to invade or expand to other parts of the body, resulting in an estimate of 9.6 million deaths worldwide in 2018. Manifold studies have been conducted to design more efficacious techniques for cancer therapy due to the inadequacy of conventional treatments including chemotherapy, surgery, and radiation therapy. With the advances in the biomedical applications of nanotechnology-based systems, nanomaterials have gained increasing attention as promising vehicles for targeted cancer therapy and optimizing treatment outcomes. Owing to their outstanding thermal, electrical, optical and chemical properties, carbon nanotubes (CNTs) have been profoundly studied to explore the various perspectives of their application in cancer treatment. The current study aims to review the role of CNTs whether as a carrier or mediator in cancer treatment for enhancing the efficacy as well as the specificity of therapy and reducing adverse side effects. This comprehensive review indicates that CNTs have the capability to be the next generation nanomaterials to actualize noninvasive targeted eradication of tumors. However, further studies are needed to evaluate the consequences of their biomedical application before the transition into clinical trials, since possible adverse effects of CNTs on biological systems have not been clearly understood.

Synthesis of magnetic gold coated poly (ε-caprolactonediol) based polyurethane/poly(N-isopropylacrylamide)-grafted-chitosan core-shell nanofibers for controlled release of paclitaxel and 5-FU

The poly (ε-caprolactonediol) based polyurethane (PCL-Diol-b-PU)/poly(N-isopropylacrylamide)-grafted-chitosan (PNIPAAm-g-chitosan) core-shell nanofibers were synthesized via coaxial electrospinning process. Paclitaxel and 5-FU anticancer drugs were incorporated into the core of nanofibers. The nanofibers surface was coated using magnetic gold nanoparticles and the potential of synthesized nanofibers was investigated for the sustained release of paclitaxel and 5-FU toward 4T1 breast cancer cells death in vitro and in vivo. The synthesized magnetic nanoparticles were characterized using SEM, TEM, XRD and DLS analysis. The surface morphology of nanofibers was studied under various applied voltage and different shell flow rates. The paclitaxel and 5-FU release profiles from nanofibers were examined under acidic and physiological pH. The maximum 4T1 cell killing was found to be 78% using magnetic gold coated-nanofibers in the presence of external magnetic field. The SEM images after incubation of nanofibers in 4T1 breast cancer cells indicated the well adhesion of cells on the nanofibers surface. The in vivo studies showed that the tumor volume did not change during 10 days. The minimum increase in tumor volume was obtained using paclitaxel and 5-FU loaded-nanofibers coated by the magnetic gold nanoparticles. The obtained results demonstrated the high therapeutic efficiency of synthesized nanofibrous carrier toward breast cancer treatment.

Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma

The alkylating agent temozolomide (TMZ) is the first-line chemotherapeutic for glioblastoma (GBM), a common and aggressive primary brain tumor in adults. However, its poor stability and unfavorable pharmacokinetic profile limit its clinical efficacy. There is an unmet need to tailor the therapeutic window of TMZ, either through complex derivatization or by utilizing pharmaceutical excipients. To enhance stability and aqueous solubility, we encapsulated TMZ in a p-sulphonatocalix[4]arene (Calix) nanocapsule and used ¹H-NMR, LC-MS, and UV-Vis spectroscopy to chart the stability of this novel TMZ@Calix complex according to FDA and European Medicines Agency guidelines. LC-MS/MS plasma stability assays were conducted in mice to further explore the stability profile of TMZ@Calix in vivo The therapeutic efficacy of TMZ@Calix was compared with that of unbound TMZ in GBM cell lines and patient-derived primary cells with known O6-methylguanine-DNA methyltransferase (MGMT) expression status and in vivo in an intracranial U87 xenograft mouse model. Encapsulation significantly enhanced the stability of TMZ in all conditions tested. TMZ@Calix was more potent than native TMZ at inhibiting the growth of established GBM cell lines and patient-derived primary lines expressing MGMT and highly resistant to TMZ. In vivo, native TMZ was rapidly degraded in mouse plasma, whereas the stability of TMZ@Calix was enhanced threefold with increased therapeutic efficacy in an orthotopic model. In the absence of new effective therapies, this novel formulation is of clinical importance, serving as an inexpensive and highly efficient treatment that could be made readily available to patients with GBM and warrants further preclinical and clinical evaluation.

Isofuranodiene synergizes with temozolomide in inducing glioma cells death

BACKGROUND

Glioblastoma multiforme (GBM) is the most common and deadly brain form of tumor. GBM exhibits high resistance to the standard treatment consisting of temozolomide (TMZ) combined with radiotherapy. Isofuranodiene (IFD) is a bioactive sesquiterpene occurring in the essential oils obtained from Alexanders (Smyrnium olusatrum L., Apiaceae). This compound has shown a broad spectrum of antitumoral activities in different human cancer cell lines both in vitro and in vivo. However, the mechanism of action of IFD on GBM and its potential effects in combination with chemotherapeutic drugs, have not been fully elucidated.

PURPOSE

The aim of the present study was to evaluate the anticancer effects of IFD itself and in combination with TMZ in GBM.

METHODS

Sulforhodamine B-based proliferation assay, cell cycle analysis and Annexin V/PI staining were carried out to determine the IFD effects on three human GBM cell lines, U87, T98, U251 and in normal human astrocyte. Modulation of protein expression levels was determined by western blot analysis. Reactive oxygen species (ROS) production was evaluated by cytofluorimetry. Moreover, the effects on cell viability of the IFD and TMZ co-administration was evaluated through the calculation of combination index (CI).

RESULTS

IFD exerted cytotoxic effects against the GBM cell lines, but not in normal cells (normal human astrocytes). This compound induced a cell cycle blockage and a necrotic cell death depending on the increase of intracellular ROS levels. Furthermore, the synergism between IFD and TMZ was demonstrated in GBM cell lines.

CONCLUSION

This study demonstrated the glioma selectivity of IFD and its cytotoxic properties suggesting a new strategy for the treatment of GBM in order to overcome the TMZ resistance and to reduce its side effects.

Recent advances in brain tumor therapy: application of electrospun nanofibers

Despite much effort to treat glioblastoma multiforme (GBM), the median survival of patients has not significantly improved. The high rate of tumor recurrence after tumor resection and the blood-brain barrier (BBB) decrease the treatment efficacy. Local drug delivery at the surgical resection site via implantable electrospun nanofibers not only circumvents the BBB, but can also reduce the rate of tumor recurrence. Nanofibers can provide a sustained release and a high concentration of chemotherapeutics at the tumor vicinity, while decreasing their systemic exposure and toxicity. In another scenario, aligned nanofibers can mimic the topographical features of the brain extracellular matrix (ECM), which can be utilized for in vitro studies on GBM cell migration. This strategy is beneficial to investigate the interactions of tumor cells with the microenvironment which has a dominant role in regulating tumor formation, progression, and metastasis.